Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danirixin In Vitro Inhibition of CD11b in RSV
NCT02201303Phase 1Completed
- Sponsor
- GSK
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danirixin in respiratory syncytial virus infection (RSV) (2 arms), sponsored by GSK. Primary endpoint: Percent inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at Day 1. Started Jan 2014; status: completed.
02
Drugs
danirixin
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02201303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201303.